Jennifer Marks: Our MET-working paper in collaboration with Caris Life Sciences
Jennifer Marks shared a post on X:
“Our MET-working paper in collaboration with Caris Life Sciences now in Lung Cancer Journal.
- METex14+ nSq have improved OS vs Sq.
- METex14 + receiving IO have improved OS compared to those who did not receive IO.
- POT1 enriched independent of histology.
- Decreased prevalence TMB-high status and TP53 mt independent of histology.
- KEAP1 and STK11 mt decreased in METex14 nSq vs Sq.
- METex14+ Sq have colder TME vs nSq.”
Source: Jennifer Marks/X
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology
Authors: Jennifer A. Marks, Nishant Gandhi, Balazs Halmos, Melina E. Marmarelis, So Yeon Kim, Lyudmila Bazhenova, Suresh S. Ramalingam, Joanne Xiu, Phillip Walker, Matthew J. Oberley, Patrick C. Ma, and Stephen V. Liu.
Jennifer Marks is is a hematology/medical oncology clinical fellow at the Lombardi Comprehensive Cancer Center of Georgetown University. Dr. Marks graduated as a Creative Premedical Scholar from Tulane University with a BFA in Musical Theater before receiving her medical degree at Tulane University School of Medicine.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023